Aethlon Medical, Inc. (NASDAQ:AEMD) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

ME Staff 8-k
-
0
Aethlon Medical, Inc. (NASDAQ:AEMD) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Aethlon Medical, Inc. (NASDAQ:AEMD) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03          Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On September 9, 2019, the Board of Directors of Aethlon Medical, Inc. (the “Company”) amended and restated the bylaws of the Company, as amended (the “Restated Bylaws”), effective as of September 9, 2019, to, among other things, update and align the Company’s bylaws with what the Company believes to be appropriate corporate governance standards.

The foregoing description of the Amended Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended Bylaws attached hereto as Exhibit 3.1 and incorporated herein by reference.

Item 9.01         Financial Statements and Exhibits

(d)       Exhibits


AETHLON MEDICAL INC Exhibit
EX-3.1 2 aethlon_8k-ex0301.htm AMENDED AND RESTATED BYLAWS Exhibit 3.1   AMENDED AND RESTATED BYLAWS of  Aethlon Medical,…
To view the full exhibit click here

About Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.